Since endometrial cancer cells express multiple angiogenic tyrosine kinase receptors, the objective in this study was to determine whether anti-angiogenic agents can be used to achieve synthetic lethality in combination with paclitaxel in p53 mutant endometrial cancer cells. Here, TP53 is linked to endometrial cancer.